The purpose of the Administrative Core is to provide all five Projects and the Cores with centralized administrative support, including clinical research management. This collaborative effort requires significant coordination of effort, integration of strategies, monitoring and oversight of various functions, and communication between the investigators. This Core will effectively and efficiently assure proper coordination among all the projects and cores, facilitating communication between investigators and especially promoting the translation of preclinical findings to the clinic. This core will be responsible for record-keeping, maintenance of protocols and their progress reports, generation of yeariy summary reports related correspondence to the NIH, and manuscript preparation. It will also assist each Individual project and core leader in the maintenance and management of their budgets, as well as arrange internal group meetings and scientific advisory board meetings. Additionally, the core will also oversee research nursing and data management for all five Projects, monitoring the timely conduct ofthe clinical studies assuring issue collection and coordinating interaction between the clinical and correlative science.
The translation of novel treatment approaches from the laboratory to the clinic is an increasingly complex undertaking that requires extensive infrastructure. This Core has the overall responsibility for assuring proper coordination, including clinical, scientific, and administrative aspects, among all the Projects and Cores. The tight integration of all the basic, translational, and clinical research initiatives allows the rapid and efficient translation of concepts to laboratory and clinical hypothesis testing.
|Kanakry, Christopher G; O'Donnell, Paul V; Furlong, Terry et al. (2014) Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. J Clin Oncol 32:3497-505|
|Fuchs, Ephraim J (2014) Transplantation tolerance: from theory to clinic. Immunol Rev 258:64-79|
|Showel, Margaret M; Brodsky, Robert A; Tsai, Hua-Ling et al. (2014) Isolated clonal cytogenetic abnormalities after high-dose therapy. Biol Blood Marrow Transplant 20:1130-8|
|Fu, Juan; Malm, Ian-James; Kadayakkara, Deepak K et al. (2014) Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors. Cancer Res 74:4042-52|
|Goswami, M; Hensel, N; Smith, B D et al. (2014) Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy tissues. Leukemia 28:1167-70|
|Agarwal, Jasmin R; Wang, Qiuju; Tanno, Toshihiko et al. (2014) Activation of liver X receptors inhibits hedgehog signaling, clonogenic growth, and self-renewal in multiple myeloma. Mol Cancer Ther 13:1873-81|
|Eapen, Mary; O'Donnell, Paul; Brunstein, Claudio G et al. (2014) Mismatched related and unrelated donors for allogeneic hematopoietic cell transplantation for adults with hematologic malignancies. Biol Blood Marrow Transplant 20:1485-92|
|Zeidan, Amer M; Forde, Patrick M; Symons, Heather et al. (2014) HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant 20:314-8|
|Gerber, Jonathan M; Gucwa, Jessica L; Esopi, David et al. (2013) Genome-wide comparison of the transcriptomes of highly enriched normal and chronic myeloid leukemia stem and progenitor cell populations. Oncotarget 4:715-28|
|Kanakry, Jennifer A; Kasamon, Yvette L; Bolanos-Meade, Javier et al. (2013) Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant 19:1514-7|
Showing the most recent 10 out of 393 publications